CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900

We determined the prognostic relevance of CD25 (IL-2 receptor-α) expression in 657 patients (≤ 60 years) with de novo acute myeloid leukemia (AML) treated in the Eastern Cooperative Oncology Group trial, E1900. We identified CD25(POS) myeloblasts in 87 patients (13%), of whom 92% had intermediate-ri...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Gönen, Mithat, Sun, Zhuoxin, Figueroa, Maria E., Patel, Jay P., Abdel-Wahab, Omar, Racevskis, Janis, Ketterling, Rhett P., Fernandez, Hugo, Rowe, Jacob M., Tallman, Martin S., Melnick, Ari, Levine, Ross L., Paietta, Elisabeth
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2012
Matèries:
Clinical Trials and Observations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3447784/
https://ncbi.nlm.nih.gov/pubmed/22855599
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-02-414425
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars